Mycoster (Ciclopirox)

Ciclopirox inhibits the synthesis of fungal sterols and disrupts membrane transport processes within fungal cells. This dual action leads to accumulation of toxic metabolites, loss of membrane integrity, and ultimately fungal cell death, thereby clearing the infection.

The dosage of Mycoster is determined by the prescribing healthcare professional based on the specific infection, its severity, and the patient’s age. Typically, a thin layer is applied to the affected area once or twice daily as directed by the prescriber.

Safety data for ciclopirox in pregnancy and lactation are limited. Healthcare providers should weigh the potential benefits against any possible risks before prescribing Mycoster to pregnant or nursing individuals. Consultation with a medical professional is essential.

To request Mycoster, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mycoster (ciclopirox) offers a broad spectrum of activity against dermatophytes and yeasts, similar to other topical agents like terbinafine or clotrimazole. Its unique mechanism of disrupting sterol synthesis and membrane transport may provide an alternative for patients who do not respond to or tolerate other classes.

Mycoster should be stored at room temperature, below 25 °C, in its original packaging. Keep the container tightly closed, protect it from moisture and direct sunlight, and ensure it is out of reach of children.

Mycoster is applied topically to clean, dry skin. A thin film should be spread over the affected area and the surrounding margin, usually once or twice daily, as instructed by the prescriber. Hands should be washed after application unless the hands are the treatment site.

While generally well tolerated, Mycoster can cause serious skin reactions such as allergic contact dermatitis, severe irritation, swelling, blistering, or rare systemic hypersensitivity. Patients should discontinue use and seek medical attention if any of these symptoms develop.

Mycoster should be avoided in individuals with known hypersensitivity to ciclopirox or any component of the formulation. It is also not recommended for use on extensive broken skin, deep fungal infections requiring systemic therapy, or in patients where a healthcare professional advises against topical antifungal use.